Ligand Pharmaceuticals Incorporated (LGND)
| Previous close | 70.37 |
| Open | 70.59 |
| Bid | 70.92 x 100 |
| Ask | 71.47 x 100 |
| Day's range | 70.59 - 72.08 |
| 52-week range | 49.24 - 94.57 |
| Volume | |
| Avg. volume | 174,588 |
| Market cap | 1.265B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 23.58 |
| EPS (TTM) | 3.03 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jul 2010 |
| 1y target est | 116.80 |
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Business WireLigand to Report First Quarter 2024 Financial Results on May 7, 2024
JUPITER, Fla., April 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
ZacksWall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
